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Abstract
In mice with temporally-induced cardiac-specific deficiency of acyl-CoA synthetase-1
(Acsl1H−/−), the heart is unable to oxidize long-chain fatty acids and relies primarily on glucose
for energy. These metabolic changes result in the development of both a spontaneous cardiac
hypertrophy and increased phosphorylated S6 kinase (S6K), a substrate of the mechanistic target
of rapamycin, mTOR. Doppler echocardiography revealed evidence of significant diastolic
dysfunction, indicated by a reduced E/A ratio and increased mean performance index, although the
deceleration time and the expression of sarco/endoplasmic reticulum calcium ATPase and
phospholambin showed no difference between genotypes. To determine the role of mTOR in the
development of cardiac hypertrophy, we treated Acsl1H−/− mice with rapamycin. Six to eight
week old Acsl1H−/− mice and their littermate controls were given i.p. tamoxifen to eliminate
cardiac Acsl1, then concomitantly treated for 10 weeks with i.p. rapamycin or vehicle alone.
Rapamycin completely blocked the enhanced ventricular S6K phosphorylation and cardiac
hypertrophy and attenuated the expression of hypertrophy-associated fetal genes, including α-
skeletal actin and B-type natriuretic peptide. mTOR activation of the related Acsl3 gene, usually
associated with pathologic hypertrophy, was also attenuated in the Acsl1H−/− hearts, indicating
that alternative pathways of fatty acid activation did not compensate for the loss of Acsl1.
Compared to controls, Acsl1H−/− hearts exhibited an 8-fold higher uptake of 2-
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deoxy[1-14C]glucose and a 35% lower uptake of the fatty acid analog 2-bromo[1-14C]palmitate.
These data indicate that Acsl1-deficiency causes diastolic dysfunction and that mTOR activation
is linked to the development of cardiac hypertrophy in Acsl1H−/− mice.
Keywords
fatty acid oxidation; mTOR; insulin resistance; gene expression; ventricular function; substrate
switching
Introduction
It has been a recurring question as to whether altered cardiomyocyte metabolism activates
pathways that lead to hypertrophy. Hypertrophied and stressed hearts increase their reliance
on glucose as a major fuel, and it has been hypothesized that this alteration in glucose
homeostasis underlies the heart’s conversion, during pathologic hypertrophy, to a fetal
pattern of gene expression [1]. However, it is unclear whether hypertrophy leads to
increased glucose use or vice versa, or whether cardiac hypertrophy is an essential
adaptation that is required to maintain normal heart function.
Long-chain acyl-CoA synthetase-1 (Acsl1), one of 5 independent Acsl isoforms, catalyzes
the activation of long-chain fatty acids to acyl-CoAs that are directed towards mitochondrial
β-oxidation [2, 3]. The Acsl1 isoform is specifically required for fatty acid oxidation in
highly oxidative tissues like heart [4], skeletal muscle [4], and brown adipose [5]. Normally,
β-oxidation provides 60–90% of the ATP required for myocardial contraction [6–8], but in
hearts from temporally-induced, multi-tissue Acsl1 deficient mice (Acsl1T−/−) or from mice
with a cardiomyocyte-specific Acsl1 deficiency (Acsl1H−/−), fatty acid oxidation in
ventricles is 90% lower than in littermate controls, and the uptake of [14C]glucose into the
heart increases 8-fold [4]. Although hypertension is not present, both Acsl1T−/− and
Acsl1H−/− cardiomyocytes become hypertrophied within 10 weeks of the temporal initiation
of the knockout [4]. In these mouse models, the altered fuel use is primary, rather than the
consequence of hypertension or hypertrophy.
Left ventricular hypertrophy (LVH) results from a variety of stresses, including ischemia,
infarction, valvular insufficiency, diabetes, and hypertension [9]. As a response to systemic
hypertension, LVH is considered to be maladaptive and pathologic because it is a stronger
predictor of morbidity and mortality than is hypertension itself [10], and hypertrophy may
ultimately result in heart failure and sudden death [9]. Pathologic hypertrophy is believed to
result from events that involve biomechanical deformation signals, activation of G-protein-
coupled receptors and their intracellular signaling pathways, and activation of the PI3K-Akt
pathway initiated by insulin and other growth signals [9]. The growth-promoting
mechanistic target of rapamycin (mTOR) kinase may be involved, because when rapamycin
is used to inhibit mTOR in several mouse models, myocardial dysfunction improves [11–
13], and the hypertrophy associated with excess thyroid hormone, constitutively active Akt,
pressure overload, or over-expressed focal adhesion kinase, diminishes [12, 14–16]. In
contrast, in a mouse model with cardiac-specific deficiency of mTOR’s partner Raptor
(Regulatory-associated protein of mTOR), a dilated cardiomyopathy ensues, with death
Paul et al. Page 2






















occurring within 6 weeks [17]. When cardiac- specific Raptor−/− hearts are challenged with
pressure overload-induced hypertrophy, dilated cardiomyopathy ensues within 1 week,
adaptive cardiomyocyte growth does not occur, and apoptosis and autophagy are enhanced
[17]. Compared to isolated working wildtype hearts, palmitate oxidation by the Raptor
knockout hearts decreased 51% and glucose oxidation increased 24%. These changes in fuel
use were attributed to declines in PPARα and PGC1α expression, paralleling decreases in
their target genes, including CPT1β, MCD-1, and SCOT, and a concomitant 2.2-fold higher
expression of GLUT1 [17].
We previously showed in hearts lacking Acsl1 that mTOR complex-1 (mTORC1) is
activated, as indicated by a 5-fold increase in phosphorylation of the mTORC1 target, p70
S6 kinase (S6K) [4], and we hypothesized that the inability to activate long-chain fatty acids
for mitochondrial oxidation initiates metabolic shifts that activate mTOR. In Acsl1-deficient
hearts, these shifts result in multiple inputs that signal the enhanced availability of glucose
and other nutrients, demonstrated by the 8-fold increase in glucose flux and increased
glucose metabolism and the higher ventricle content of amino acids. Although both Acsl1-
deficient models have activated mTORC1, only the multi-tissue Acsl1T−/− mice have
diminished phosphorylation of AMP-activated kinase (AMPK) [4], an inhibitor of mTORC1
signaling [18]. Cardiac hypertrophy was judged to be pathologic in both Acsl1T−/− and
Acsl1H−/− hearts because of the upregulation of the fetal genes, α-skeletal actin, brain
natriuretic peptide, and Acsl3. We hypothesized that the cardiomyocyte hypertrophy that
develops in Acsl1-deficient hearts results from the promotion of cardiac remodeling and
hypertrophy by mTORC1. We treated Acsl1H−/− mice and their littermate controls with
rapamycin to determine whether hypertrophy in this metabolic model resulted from mTOR
activation, and, if so, whether the hypertrophy was required to maintain normal systolic
function when Acsl1 deficiency impaired the use of fatty acids for energy production.
Materials and Methods
Animal Treatment
Mouse protocols were approved by the University of North Carolina Institutional Animal
Care and Use Committee and conformed to the NIH Guide for the Care and Use of
Laboratory Animals. Mice were housed in a pathogen-free barrier facility (12 h light/dark
cycle) with free access to water and food (Prolab RMH 3000 SP76 chow). Mice with Loxp
sequences inserted on either side of exon 2 in the Acsl1 gene were backcrossed to the
C57Bl/6J strain six times and then interbred with mice in which Cre expression is driven by
an α-myosin heavy chain promoter that is induced by tamoxifen (B6.Cg-Tg(Myh6-cre/
Esr1)1Jmk/J, Jackson Labs) to generate tamoxifen-inducible, heart-specific Acsl1H−/−
knockout mice. Six to 8 week old Acsl1H−/− and littermate Acsl1flox/flox control male mice
were injected i.p. with tamoxifen (Sigma, St. Louis, MO) (75 mg/kg BW), dissolved in corn
oil (20 mg/ml) for 4 consecutive days (3 mg/40 g body weight). Starting on the next day,
subgroups of mice were injected daily i.p. for either 2 weeks or 10 weeks with rapamycin (1
mg/kg in PBS/8% ethanol, 10% Tween 20/10% PEG-400) or with the vehicle alone. Ten
weeks after tamoxifen induction, the mice were anesthetized with avertin and heart
ventricles were removed and snap frozen in liquid nitrogen. To isolate total membranes,
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hearts were homogenized with 10 up-and-down strokes, using a motor-driven Teflon pestle
and glass mortar in ice-cold buffer (10 mM Tris [pH 7.4], 1mM EDTA, 0.25 M sucrose, 1
mM dithiothreitol). Homogenates were centrifuged at 100,000 x g for 1 h at 4°C. The
membrane pellet was then resuspended in buffer. Protein content was determined by the
BCA assay (Pierce, Rockford, IL) with BSA as the standard. Plasma was collected from
mice in 10% 0.5 M EDTA. Glucose tolerance tests were performed by i.p. injection with D-
glucose (2.5 g/kg body wt), and tail blood glucose was measured at baseline, 15, 30, 60, and
120 min using a One Touch Ultra glucometer (Lifescan, Inc., Milpitas, CA).
Echocardiography and Doppler Analysis
Cardiac echocardiography was performed (blinded to mouse type and treatment) on
conscious mice at the indicated time points using a VisualSonics Vevo 770 or Vevo 2100
ultrasound biomicroscopy system (VisualSonics, Inc., Toronto, Ontario, Canada). A model
707B (30 MHz) or model MS-550D (22–55 MHz) scan head was used on the Vevo 770 and
Vevo 2100, respectively, as previously described [19]. Two dimensional guided M-mode
echocardiography was performed in the parasternal long-axis view at the level of the
papillary muscle on loosely restrained conscious mice. Wall thickness was then determined
by measurements of epicardial to endocardial leading edges. Doppler analysis of the mitral
valve to determine the mitral inflow velocity was performed on lightly anesthetized mice
(2% (vol/vol) isoflurane/100% oxygen) as previously described [4, 20, 21]. Mitral valve
flow Doppler was acquired by positioning the transducer angled cranially in a supine mouse
at 45 degrees in an epigastric position to achieve an apical four-chamber view. Peak E and A
heights were determined on mitral valve sequential waveforms in at least 5 waveforms. The
mean performance index (ICT+IRT/ET) is calculated as the isovolumetric contraction time
(ICT) plus the isovolumetric relaxation time (IRT) divided by the ejection time [22, 23]. E-
wave deceleration time (DT) was also measured. These measures were determined by
Doppler waveform analyses of the mitral valve (as described above) and aortic valve along
with EKG measurements to ensure the correct waveform times. The mean performance
index (MPI; (ICT + ET+IRT)−ET/ET) can determine if either systolic or diastolic
dysfunction is present [24, 25] and has been successfully used in mice [26]. M-mode and
Doppler measurement data represent 3–6 averaged cardiac cycles from at least 2 scans per
mouse.
Acsl assay
Acsl initial rates were measured with 50 μM [1-14C]palmitic acid (Perkin Elmer, Waltham,
MA), 10 mM ATP, and 0.25 mM CoA in total membrane fractions from ventricles (2–6 μg
protein) [27]. This assay measures the total ATP-mediated activation of long-chain fatty
acids by long-chain Acsl isoforms plus very-long-chain Acsl isoforms (ACSVL, also called
FATP). No Acsl activity was measurable in the soluble (cytosolic) fraction.
RT-PCR
Total RNA was isolated from heart ventricles (RNeasy Fibrous Tissues Kit, Qiagen,
Alameda, CA). cDNA was amplified by real-time PCR using SYBR Green (Applied
Biosystems, Foster City, CA) detection with specific primers for the gene of interest and
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normalized to Gapdh or Tubulin and expressed as arbitrary units of 2−ΔCT relative to the
control group (Table 2).
Immunoblots
Total protein lysates were isolated in lysis buffer (20 mM Tris base, 1% Triton-X-100, 50
mM NaCl, 250 mM sucrose, 50 mM NaF, 5 mM Na2P2O7, plus protease inhibitor
(#11836153 Roche, Florence, SC). Equal amounts of protein (40–60 μg) were loaded and
resolved on 10% SDS polyacrylamide gels and transferred to nitrocellulose membranes.
Blots were probed with antibodies against P-p70 S6K (Thr389) and were then stripped and
reprobed with p70 S6K.
2-Deoxyglucose and 2-bromopalmitate uptake
Anesthetized mice were injected retro-orbitally with 5 μCi 2-deoxy[1-14C]glucose in saline
or 1.5 μCi 2-bromo-[1-14C]palmitate complexed to BSA in PBS (Moravek Biochemicals,
Brea, CA) Tissues were harvested and flash frozen in liquid N2 30 min after injection.
Radioactivity was measured in tissue homogenates by scintillation and normalized to the
number of DPM present in 10 μl of serum obtained 5 min after injection ((dpm/mg
tissue)/dpm in 10 μl serum).
Statistics
Data are presented as mean ± SE for each treatment group. Differences between treatment
groups were evaluated by one-way ANOVA with Tukey multiple-comparison posttests. All
statistical analyses were performed using GraphPad Prism (version 5.0; GraphPad Software,
San Diego CA). Differences between means with p <0.05 were considered statistically
significant.
Results
Rapamycin inhibited Acsl1H−/− -induced spontaneous cardiac hypertrophy
Compared to vehicle-treated controls, 10 weeks after tamoxifen induction, Acsl1H−/−
deficient mice developed a spontaneous cardiac hypertrophy (Table 1) [4]. Hypertrophy was
confirmed by echocardiographic analysis in which both anterior and posterior wall thickness
indices (IVS, LVPW) and the LV mass were significantly increased compared to sibling
controls (Table 1). Because our previous studies identified activated mTOR and its
downstream target, phosphorylated p70 S6 kinase, we treated mice with rapamycin to inhibit
mTOR in order to determine directly whether mTOR links Acsl1 deficiency with the
observed cardiac hypertrophy.
When Acsl1H−/− deficient mice induced with tamoxifen were treated with rapamycin, the
spontaneous hypertrophy observed in Acsl1H−/− deficient mice was inhibited, as evidenced
by wall thickness indices and LV mass measurements that did not differ from littermate
controls (Table 1), as well as the inhibition of increases in heart weight (Fig. 1). Although
Acsl1H−/− deficient mice did not exhibit systolic dysfunction (Table 1), we asked whether
they had evidence of diastolic dysfunction in vivo. Doppler analysis of blood flow through
the mitral and aortic valves was performed in control and Acsl1H−/− mice with and without
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treatment with rapamycin, to determine the E/A ratio and the mean performance index as
indicators of diastolic and diastolic/systolic dysfunction, respectively (Fig. 1, Table 3). At 2
weeks after tamoxifen treatment, when total Acsl activity has decreased by 50% [4], the
diastolic function was normal in both vehicle-treated Acsl1H−/− mice. However, because
rapamycin itself caused mild diastolic dysfunction in both control and knockout animals at 2
weeks (data not shown), these latter results cannot be interpreted. By 10 weeks, however,
vehicle-treated Acsl1H−/− mice exhibited a nearly 50% decline in diastolic function and a
parallel increase of >50% in mean performance index (Fig. 2A–C), consistent with a defect
in diastolic function. The mitral deceleration time did not change (Table 3), and the mRNA
expression of SERCA (sarco/endoplasmic reticulum calcium ATPase) and its
phospholambin regulator (PLN), which are frequently, but not invariably [28, 29],
diminished with diastolic dysfunction, were not altered in Acsl1H−/− mice before or after
rapamycin treatment (SERCA1/2: vehicle control, 1.11±0.24; rapamycin control, 1.41±0.35;
vehicle Acsl1H−/−, 0.83±0.09; rapamycin Acsl1H−/−, 1.16±0.15; PLN: vehicle control,
1.11±0.0.21; rapamycin control, 1.33±0.25; vehicle Acsl1H−/−, 0.85±0.09; rapamycin
Acsl1H−/−, 1.23±0.14; n=5–6). Because the 10 week rapamycin treatment itself induced
diastolic dysfunction in both control and Acsl1 deficient mice, as previously described [30–
32], it was not possible to interpret the effects of Acsl1-related mTOR activity on diastolic
function.
Pathologic cardiac hypertrophy is usually accompanied by upregulation of genes that are
normally expressed in fetal hearts [33], and we previously reported increases in the mRNAs
for α-Ska and Bnp in heart from the multi-tissue knockout of Acsl1 [4]. Similar to its effect
in Acsl1H−/− ventricles on the fetally-expressed gene Acsl3, the rapamycin-mediated block
of hypertrophy also diminished the expression of α-Ska and Bnp, and it normalized the
lowered expression of the ventricle pathogenic marker, atrial natriuretic factor (Anf) (Fig. 3).
Rapamycin reversed the Acsl1 deficiency-induced phosphorylation of p70 S6 kinase in
Acsl1H−/− mice
Compared to their littermate controls, the absence of Acsl1 resulted in the activation of
mTOR in cardiac ventricles, confirmed by the markedly enhanced phosphorylation of p70
S6 kinase (Fig. 4A). Treatment with rapamycin for 10 wk completely blocked this enhanced
S6K phosphorylation. By 10 weeks after inducing the MHC-mediated cre recombinase with
tamoxifen, Acsl1 mRNA was virtually absent in both vehicle-treated and rapamycin-treated
ventricles (Fig. 4B). Other Acsl isoforms contributed only 10% of total Acsl activity in the
heart (Fig. 5A) and did not compensate functionally for the loss of Acsl1. The expression of
Acsl4, 5, and 6 did not change (Fig. 4B), but Acsl3 mRNA, the major isoform expressed in
fetal heart [34], increased 2.5-fold, probably because pathologic hypertrophy causes fetal
gene expression to increase [1, 35]. Treatment with rapamycin normalized the increase in
Acsl3 expression, but had no effect on other Acsl isoforms and did not alter the amount of
residual Acsl activity (Fig. 5A).
Rapamycin treatment had no effect on Acsl activity or the altered fuel uptake
In the heart, activation of long-chain fatty acids by Acsl1 is required for their subsequent
metabolism by mitochondrial β-oxidation [4]. Compared to controls, Acsl specific activity
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with the long-chain fatty acid palmitate was 90% lower in both vehicle- and rapamycin-
treated ventricles (Fig. 5A), and the uptake of the non-metabolizable fatty acid analog 2-
bromo-[14C]palmitate was markedly lower (Fig. 5B). Consistent with the diminished ability
of the Acsl1H−/− ventricles to use fatty acid as its primary fuel, ventricle uptake of the non-
metabolizable glucose analog 2-deoxy-[14C]glucose was 7.9-fold higher in the Acsl1H−/−
ventricles; this enhanced uptake was unchanged by rapamycin treatment (Fig. 5C).
Surprisingly, despite the marked increase in the uptake of 2-deoxy-[14C]glucose, the
expression of both Glut1 and Glut4 mRNA was lower in Acsl1H−/− mice than in controls,
showing a discrepancy between glucose transport and transporter mRNAs (Fig. 5D).
Rapamycin treatment had no effect on mouse weight (Fig. 1A), but the drug abrogated the
hypertrophy that develops in hearts that lack Acsl1 [4] (Fig. 1B, C), even though the
Acsl1H−/− hearts continued to remain highly dependent on glucose. In the control
Acsl1flox/flox hearts, however, rapamycin treatment increased the uptake of 2-
deoxy[14C]glucose (Fig. 5C), likely because long-term treatment with rapamycin inhibits
mTORC2-mediated phosphorylation of Akt, thereby inducing glucose intolerance, as shown
by glucose tolerance tests performed in vehicle- and rapamycin-treated mice (Fig. 5E) [36].
Discussion
The 90% decrease in total Acsl activity in both Acsl1T−/− and Acsl1H−/− heart ventricles [4]
shows that Acsl1 is the major Acsl isoform in heart. Acsl1, a 78 kDa protein with a predicted
N-terminal transmembrane domain, is located on several intracellular organelles, including
the outer mitochondrial membrane where, in heart and adipose tissue, it appears to direct
long-chain fatty acids into the mitochondria for β-oxidation. When Acsl1 is missing in white
or brown adipose tissue [5] or in cardiomyocytes [4], the oxidation of palmitate (and of
oleate or linoleate; data not shown) is reduced by more than 80%. Consequently, the
deficient tissues must rely on glycolysis and the oxidation of glucose to provide fuel for
normal function. In beating hearts, the inability to use fatty acids results in a compensatory
8-fold increase in glucose uptake, and the subsequent enhancement in glucose flux and
metabolism upregulates mTORC1 [4], a complex in which mTOR kinase associates with
several partners including Raptor and Pras40, to phosphorylate p70 S6K, thereby facilitating
the translational control of protein synthesis [37]. The upregulation of mTOR in Acsl1H−/−
hearts that depend on glucose as their major energy substrate is reminiscent of the activation
of mTOR in isolated rat hearts stimulated to contract in the presence of a high glucose load
[38], in the contractile impairment caused by cardiac over-expression of GLUT1 that
increases glucose uptake in the context of a high fat diet [39], and in CD36-null mouse
hearts which have diastolic dysfunction [40]. Pathologic hypertrophy is generally
accompanied by the upregulation in ventricles of fetal genes like α-Ska and Bnp [1, 41], as
observed in Acsl1T−/− [4] and Acsl1H−/− ventricles.
mTORC1 is activated by nutrients that signal the availability of sufficient substrate and
energy for growth. Thus, mTOR activity is increased by elevated plasma insulin [42] and by
tissue branched chain amino acids, particularly leucine [43]. mTOR is also activated by
hypertension [44]. None of these features were present in Acsl1-deficient mice [4], but,
other positive nutrient signals were prominent, including an increase in general amino acid
availability and enhanced glycolytic flux [45]. Insulin-dependent activation of mTOR
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requires glucose phosphorylation [45], and mTOR is active when activated cellular AMPK
is low, but unlike the 3-fold higher ventricle content of glucose-6-phosphate and the low
AMPK activity in the multi-tissue knockout of Acsl1 (Acsl1T−/−) [4], the Acsl1H−/− heart-
specific model had unaltered glucose-6-phosphate content and a phosphoAMPK/total
AMPK ratio that was increased relative to that of controls (data not shown). Despite the
increased uptake of 2-deoxy-[14C]glucose, mRNA expression of Glut1 and Glut4 were
actually lower in Acsl1H−/− hearts. Glut1 and Glut4 are among the most abundant Glut
transcripts in heart, but their expression varies in mouse cardiac dysfunction models [46],
and both isoforms are downregulated 80% in failing human hearts [47]. These decreases are
thought to be a manifestation of the heart reversion to a fetal metabolic profile, which is also
supported by the increases in α-Ska and Bnp expression in the Acsl1H−/− hearts.
mTORC1 is highly sensitive to rapamycin, and chronic treatment with rapamycin also
disturbs mTORC2 signaling by blocking the association of mTOR with its partner Rictor
(Raptor-independent companion of mTOR) [48]. Although upregulating mTORC1
diminishes insulin-induced phosphorylation of IRS-1(Ser636/Ser639) and treatment with
rapamycin acutely reverses this phosphorylation [49], chronic rapamycin treatment disrupts
mTORC2 and suppresses its ability to phosphorylate Akt at S473, thereby lessening insulin
signaling [36]. In addition to disrupting insulin signaling in peripheral tissues, rapamycin is
toxic for β-cells and diminishes insulin secretion [50]. As previously reported in mice and
humans [51], treatment with rapamycin for 10 weeks caused marked glucose intolerance to
develop in the Acsl1H−/− mice. Thus, in the present study, glucose intolerance rapidly
resulted from inhibition of both mTORC1 and mTORC2.
Based on Doppler echocardiography, the Acsl1H−/− mice had a significant decrease in
diastolic function. However, the normal deceleration time suggests that this represents an
early stage of diminished function [52], and the normal expression of SERCA and
phospholambin suggest that calcium loading is not likely to be responsible [29].
Interestingly, although rapamycin inhibited the increased cardiac growth in the Acsl1H−/−
mice, it did not appear to relieve the diastolic dysfunction. This finding was confounded by
the fact that rapamycin treatment of control mice for as little as 2 weeks induced its own
mild diastolic dysfunction. However, because Acsl1H−/− hearts were not affected to a
greater extent than control mice, these data suggest that the cardiac hypertrophy is driven by
the ability of the increased glucose flux to activate mTORC1, independent of the
mechanisms by which Acsl1H−/− diastolic dysfunction occurs. Rapamycin analogs are given
as immunosuppressants after organ transplantation, but rapamycin-related abnormalities in
cardiac diastolic function have not been observed [53–55]. In fact, in humans with age-
induced activated mTOR, caloric restriction diminishes diastolic dysfunction [56], and in
cardiac transplantation patients, sirolimus treatment is associated with improved diastolic
function [57].
The dependence on glucose of Acsl1-deficient hearts allowed us to re-examine the problem
of fuel metabolism and hypertrophy. Although the adult heart normally relies on long chain
fatty acids for 60–90% of its fuel, it is believed that the heart functions best when it retains
metabolic flexibility and can switch readily between the use of fatty acid and glucose
substrates [58]. Numerous studies have reported preferential cardiac use of fatty acid during
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fasting and diabetes [59, 60], whereas use of glucose is higher with hypoxia or failure [61–
63]. Despite cardiac hypertrophy in Acsl1-deficient hearts, systolic function remained
normal, and when transverse arch banding was performed, control and Acsl1T−/− mice
responded similarly to the increased pressure overload; heart weight doubled and fractional
shortening decreased to ~40% in hearts from both genotypes [4]. The, elevations in the
expression of fetal marker genes normally associated with pathologic hypertrophy, α-Ska,
Bnp, and Acsl3, all decreased with rapamycin treatment, suggesting that their increased
expression had resulted directly from the activation of mTORC1, and not from an
underlying cardiomyocyte problem related to fuel use or energy production. Although Anf
expression increases when hypertrophy develops after transverse aortic constriction [64],
Anf expression was diminished in Acsl1H−/− ventricles but was normalized by rapamycin
treatment.
In summary, this study strongly indicates that the cardiac hypertrophy observed in Acsl1H−/−
mice occurs secondary to the mTORC1 activation that results from enhanced glycolytic flux,
although mTORC2 might also be playing a role. Systolic function in Acsl1H−/− mice
remains normal in older animals [4], and ventricular hypertrophy was not required to
support normal systolic function or to prevent worsening of diastolic dysfunction. Although
these data suggest the possibility that abrogation of cardiac hypertrophy might be useful, the
detrimental effects of rapamycin on glucose metabolism warrant additional investigation.
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Mice with heart-specific acyl-CoA synthetase-1 deficiency cannot oxidize fatty acids
Acsl1H−/− hearts depend primarily on glucose for energy
Echocardiography showed that Acsl1H−/− hearts have significant diastolic
dysfunction
Rapamycin treatment showed that activated mTORC1 causes cardiac hypertrophy
Cardiac hypertrophy was not required to maintain normal systolic function
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Rapamycin treatment diminished cardiac hypertrophy. A) Body weight of control and
Acsl1H−/− mice. B) Absolute heart weight and C) relative heart weight (heart weight/tibia
length) in control and Acsl1H−/− mice treated with vehicle (Veh) or rapamycin (Rapa). The
values are means plus SEMs (error bars). *, p < 0.05 compared with littermate controls. n =
6–10 per group.
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Acsl1H−/− mice exhibited diastolic dysfunction. A) E/A ratio (ratio between early (E) and
late (atrial - A) ventricular filling velocity) (n = 4–6 per group); and B) MPI (mean
performance index) (n = 4–6 per group) in control and Acsl1H−/− mice. C) Representative
mitral valve Doppler analysis (n = 8–9 per group). The values are means plus SEMs (error
bars). *, p < 0.05 compared with littermate controls.
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Rapamycin treatment of Acsl1H−/− mice attenuated the expression of pathologic
hypertrophy markers. mRNA abundance of fetal gene markers, α-skeletal actin (α-Ska), B-
type natriuretic peptide (Bnp), and atrial natriuretic factor (ANF) in ventricles from control
and Acsl1H−/− mice treated with vehicle (Veh) or rapamycin (Rapa). The values are means
plus SEMs (error bars). Values that are significantly different (p <0.05) from the values for
the control are indicated by an asterisk. n = 3 per group.
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Rapamycin reversed the upregulated phosphorylation of p70 S6 kinase in Acsl1H−/− mice
and diminished the expression of Acsl3 mRNA. A) Representative immunoblot from male
mice were treated with vehicle (Veh) or rapamycin (1 mg/kg) daily i.p. (Rapa) from 1 wk
after tamoxifen treatment until sacrifice 10 wk after the tamoxifen treatment. Total (p70
S6K) and phosphorylated p70 S6K (P-p70 S6K) at Thr389 in ventricles from control and
Acsl1H−/− mice. n=4. B) Acsl isoenzyme mRNA abundance in ventricles from control and
Acsl1H−/− mice treated with vehicle or rapamycin. n = 3–6. The values are means plus
SEMs (error bars). *, p<.05.
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Rapamycin treatment had no effect on Acsl activity or the altered fuel uptake, but caused
glucose intolerance. A) Acsl specific activity in ventricles from control and Acsl1H−/− mice
treated with vehicle (Veh) or rapamycin (Rapa). B) Uptake of 2-bromo[1-14C]palmitate into
the ventricles of control and Acsl1H−/− mice. C) 2-Deoxy[1-14C]glucose uptake into the
ventricles of control and Acsl1H−/− mice treated with vehicle or rapamycin. n = 3–5 per
group. D) mRNA abundance of Glut1 and Glut4 in ventricles from control and Acsl1H−/−
mice treated with vehicle (Veh) or rapamycin (Rapa). The values show means plus SEMs
(error bars); *, p<.005 compared with littermate controls and #, p<.03 compared with
vehicle control. n = 5–6 per group. E) Plasma glucose at intervals after i.p. glucose (2.5 g/kg
body wt) in control and Acsl1H−/− mice treated with vehicle or rapamycin. n = 5 per group.
Paul et al. Page 19











































Paul et al. Page 20
Table 1










Heart Rate (bpm) 660.0 ± 33.8 650.1 ± 18.2 675.8 ± 28.9 686.1 ± 22.7
IVS,d (mm) 1.13 ± 0.05 1.32 ± 0.08* 1.00 ± 0.05 1.11 ± 0.05
LVID,d (mm) 2.69 ± 0.13 2.70 ± 0.13 2.83 ± 0.11 2.60 ± 0.06
LVPW,d (mm) 1.04 ± 0.05 1.18 ± 0.06* 0.94 ± 0.05 1.04 ± 0.05
IVS,s (mm) 1.71 ± 0.07 1.94 ± 0.06* 1.62 ± 0.13 1.70 ± 0.05
LVID,s (mm) 1.37 ± 0.15 1.27 ± 0.11 1.32 ± 0.12 1.16 ± 0.07
LVPW,s (mm) 1.50 ± 0.06 1.85 ± 0.07* 1.50 ± 0.09 1.56 ± 0.04
LV Vol;d (μl) 27.1 ± 3.4 27.8 ± 3.2 30.6 ± 2.7 24.9 ± 1.4
LV Vol;s (μl) 5.2 ± 1.4 4.4 ± 1.0 4.6 ±1.1 3.3 ± 0.5
FS (%) 49.1 ± 4.4 53.1 ± 2.9 53.6 ± 3.0 55.4 ± 1.7
EF (%) 81.4 ± 4.0 84.8 ± 2.6 85.4 ± 2.8 87.2 ± 1.3
LV Mass (mg) 99.9 ± 0.8 128.3 ± 7.5* 90.6 ± 5.9 95.2 ± 6.2
Differences between treatment groups were evaluated by one-way ANOVA, followed by an all pairwise Holm-Sidak multiple comparison
procedure; *p<≤0.05 versus all other groups.
IVS, interventricular septum; LVID, left ventricular inner diameter; LVPW, left ventricular posterior wall; LV Vol, left ventricular volume; % EF,
ejection fraction; fractional shortening; LV, left ventricular; d, diastole; s, systole. Data represent mean ± SEM;
*
p<0.05.
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Table 2

















Abbreviations: Acsl, acyl-CoA synthetase; Anf, atrial natriuretic factor; α-Ska, α-skeletal actin; Asns, asparagine synthetase; Bnp, B-type natriuretic
peptide; Gapdh, glyceraldehyde 3-phosphate dehydrogenase; Glut, glucose transporter; PLN, phospholambin; SERCA, sarco/endoplasmic
reticulum calcium ATPase
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Table 3





n=7 (n=6 for DT)
Vehicle
ET (ms) 51.0 ± 2.9 45.1 ± 1.8
IRT (ms) 16.1 ± 1.8 16.1 ± 1.8
ICT+ET+IRT (ms) 60.4 ± 2.4 65.8 ± 5.4
MPI 0.20 ± 0.06 0.48 ± 0.10*
E (mm/s) 683.3 ± 22.2 564.6 ± 41.6*
A (mm/s) 374.3 ± 35.7 553.0 ± 37.0*
E/A Ratio 1.92 ± 0.18 1.04 ± 0.08*
DT (ms) 19.2 ± 3.7 18.8 ± 4.0
E (early) and A (atrial) ventricular filling velocity; ET, ejection time; IRT, isovolumetric relaxation time; ICT, isovolumetric contraction time;
MPI, mean performance index =(ICT+ET+IRT)−ET/ET); DT, mitral deceleration time. Data represent mean ± SEM;
*
p<0.05 (T-test).
Biochim Biophys Acta. Author manuscript; available in PMC 2015 June 01.
